 LA JOLLA, Calif., May 12, 2021 PRNewswire -- Avidity Biosciences, Inc. Nasdaq: RNA, a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates AOCsTM, today reported financial results for the first quarter ended March 31, 2021 and highlighted recent corporate progress. 